Agile Computing Authors: John Mertic, Elizabeth White, Ruxit Blog, Liz McMillan, Pat Romanski

News Feed Item

Rumors, News and Biotech Buzz Present Various Trade Opportunities

LOS ANGELES, CA -- (Marketwire) -- 01/18/13 -- A significant bunch of biotech deals were being discussed and closed at the recent biotech conferences in San Francisco.

Investors of all sizes were wagging their tongues about a number of upcoming developments and new opportunities in the market (bullish) following a busy week of presentations and simultaneous financial gatherings in the city by the bay. It looks to us like 2013 may be marked as a year of heavy biotech IPOs.

One particular privately held firm that may be looking to go public, caught our attention with their proposed once-a-week injectable basal insulin that is currently in preclinical development. AntriaBio's product looked highly intriguing as the formulation has been designed to release insulin slowly and uniformly over a period of seven days without an adverse initial burst of insulin. The subcutaneous injection would target a huge market of patients with type 1 and type 2 diabetes for the control of hyperglycemia. No official word yet on whether the firm is going to become publicly traded, but retail biotech investors seemed intrigued by the innovation which stemmed from nearby Menlo Park. Driving some of the excitement was the fact that the product has a history of development and venture capital with support from a top-notch management team behind it.

On the public side, we heard several rumors involving some of the stocks we've covered in this space, starting with two Israeli firms -- Pluristem Therapeutics Inc. (NASDAQ: PSTI) and Medgenics, Inc. We remain very bullish on both firms given important upcoming catalysts that some retail investors appear to have lost track of.

In addition to an almost certain Orphan Drug Designation that could be announced at any moment, Pluristem is also due to receive a very large multi-million dollar milestone payment tied to their progress of the development of PLX cells for the treatment of Pulmonary Hypertension from United Therapeutics.

Interestingly, there was also loud chatter about possible courtship activity involving Pluristem and a big pharma. Some mentioned both United Therapeutics (again) and Lonza as possible deal partners. Either would provide skeptics with further validation of Pluristem's various platforms which address several growing markets.

It's no secret that Lonza ($3.14B market cap) provides emerging and established innovators of novel therapeutics with expertise and advanced technologies while United Therapeutics ($2.65B market cap) already knows the firm, having signed an agreement with them in June of 2011. Under the terms of that agreement, United Therapeutics made an upfront payment of $7 million and Pluristem is eligible to receive regulatory milestone payments and other payments accumulating together with the upfront payment to a total of approximately $55 million and reimbursement of costs of its development and clinical activities. There are clearly a growing number of misguided shorts in the stock which run the risk of being intemperately squeezed at any moment. We would advise accumulating at these price levels given the discounted prices, very healthy cash position and multiple possibilities for strong catalyst reactions.

Speaking of catalysts, our favorite low-float biotech Medgenics is also rumored to be on the verge of announcing some important milestone developments in their quest to help solve the world-wide hepatitis epidemic. We are watching their progress on multiple fronts closely, as the stock tends to move up quickly on positive news. Medgenics' sustained production and delivery of interferon-alpha for the treatment of hepatitis using their INFRADURE™ technology has been drawing attention from experts in the field.

As we see across the biotech landscape, a number of competitors are scrambling and failing to fill the need for PEG-interferon and ribavirin therapy, the current standard known all too painfully to patients of the hepatitis virus. The race is on for an effective treatment that can improve patient compliance and reduce side effects.

A bet on Medgenics' own "miniature bio pump," which is impacted into the patient and continuously produces and releases the desired protein into the body, could pay off big -- especially when one considers that the technology has multiple applications in several billion dollar markets.

One stock we get a lot of e-mail about is the penny-priced, Phase III drug developer CEL-SCI Corp. (NYSE MKT: CVM). In December, they raised another round of gross proceeds, this time a total of approximately $10.5 million through a registered offering to institutional investors.

We've been seeing an increasing number of big block trades in that stock. It's logical to assume that some of those investors are expecting positive announcements involving further expansion of the firm's Phase III study of their immunotherapeutic agent Multikine® (Leukocyte Interleukin Injection), which is being developed as a potential first-line treatment for advanced primary head and neck cancer. Each time they have raised money, the firm has successfully and steadily been increasing the number of patients and clinical study sites with an eye on accelerating the approval process.

Still, other investors who know the company and follow the company may be taking positions as the already overly-aggressive flu season kicks off. We all know that this is a stock that tends to peak in the winter months because of the firm's activities in that space.

In a recent shareholder letter, CEO Geert Kersten stated that CEl-SCI's L.E.A.P.S. collaborative study with the National Institutes for Allergy and Infectious Diseases (NIAID) on pandemic flu was progressing well. "The testing conducted by NIAID with our L.E.A.P.S. compounds has shown significant promise in animal models of the disease and has been submitted for publication," said Kersten. "We believe that the data will potentially be very relevant when the next strain of drug resistant flu makes an appearance."

Finally, while it continues to trade sideways, we are seeing increased volume and attention being paid to Lpath, Inc. (NASDAQ: LPTN). That firm continues late-stage clinical testing and development of their product candidates iSONEP™ and ASONEP™ which target bioactive signaling lipids in order to treat diseases like Wet AMD, cancer, inflammation, fibrosis and a host of other indications. The stock appears to be getting close to eating through all of the over-hang left from the December 13th share offering which provided just under $12 million to the company.

We are paying particularly close attention to iSONEP™ which is being developed via a partnership with Pfizer (announced in December of 2010). That potential treatment for Wet AMD targets nearly 2 million patients in the U.S. alone and a positive outcome of that clinical trial could be enough to get Lpath taken out via a long rumored buy-out. We love the shares at these prices and the fact that the firm is now on a major exchange.

Disclosure: None

The full report including charts and technical analysis is available at:


Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

Follow Us

News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com
BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Contacts Only:
M. Davila
Assistant Editor
e-mail: Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
DevOps is being widely accepted (if not fully adopted) as essential in enterprise IT. But as Enterprise DevOps gains maturity, expands scope, and increases velocity, the need for data-driven decisions across teams becomes more acute. DevOps teams in any modern business must wrangle the ‘digital exhaust’ from the delivery toolchain, "pervasive" and "cognitive" computing, APIs and services, mobile devices and applications, the Internet of Things, and now even blockchain. In this power panel at @...
If you had a chance to enter on the ground level of the largest e-commerce market in the world – would you? China is the world’s most populated country with the second largest economy and the world’s fastest growing market. It is estimated that by 2018 the Chinese market will be reaching over $30 billion in gaming revenue alone. Admittedly for a foreign company, doing business in China can be challenging. Often changing laws, administrative regulations and the often inscrutable Chinese Interne...
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
SYS-CON Events announced today that Streamlyzer will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Streamlyzer is a powerful analytics for video streaming service that enables video streaming providers to monitor and analyze QoE (Quality-of-Experience) from end-user devices in real time.
You have great SaaS business app ideas. You want to turn your idea quickly into a functional and engaging proof of concept. You need to be able to modify it to meet customers' needs, and you need to deliver a complete and secure SaaS application. How could you achieve all the above and yet avoid unforeseen IT requirements that add unnecessary cost and complexity? You also want your app to be responsive in any device at any time. In his session at 19th Cloud Expo, Mark Allen, General Manager of...
SYS-CON Events announced today that Pulzze Systems will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems, Inc. provides infrastructure products for the Internet of Things to enable any connected device and system to carry out matched operations without programming. For more information, visit http://www.pulzzesystems.com.
One of biggest questions about Big Data is “How do we harness all that information for business use quickly and effectively?” Geographic Information Systems (GIS) or spatial technology is about more than making maps, but adding critical context and meaning to data of all types, coming from all different channels – even sensors. In his session at @ThingsExpo, William (Bill) Meehan, director of utility solutions for Esri, will take a closer look at the current state of spatial technology and ar...
Cloud based infrastructure deployment is becoming more and more appealing to customers, from Fortune 500 companies to SMEs due to its pay-as-you-go model. Enterprise storage vendors are able to reach out to these customers by integrating in cloud based deployments; this needs adaptability and interoperability of the products confirming to cloud standards such as OpenStack, CloudStack, or Azure. As compared to off the shelf commodity storage, enterprise storages by its reliability, high-availabil...
The IoT industry is now at a crossroads, between the fast-paced innovation of technologies and the pending mass adoption by global enterprises. The complexity of combining rapidly evolving technologies and the need to establish practices for market acceleration pose a strong challenge to global enterprises as well as IoT vendors. In his session at @ThingsExpo, Clark Smith, senior product manager for Numerex, will discuss how Numerex, as an experienced, established IoT provider, has embraced a ...
In past @ThingsExpo presentations, Joseph di Paolantonio has explored how various Internet of Things (IoT) and data management and analytics (DMA) solution spaces will come together as sensor analytics ecosystems. This year, in his session at @ThingsExpo, Joseph di Paolantonio from DataArchon, will be adding the numerous Transportation areas, from autonomous vehicles to “Uber for containers.” While IoT data in any one area of Transportation will have a huge impact in that area, combining sensor...
In the next forty months – just over three years – businesses will undergo extraordinary changes. The exponential growth of digitization and machine learning will see a step function change in how businesses create value, satisfy customers, and outperform their competition. In the next forty months companies will take the actions that will see them get to the next level of the game called Capitalism. Or they won’t – game over. The winners of today and tomorrow think differently, follow different...
“Media Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. CloudBerry Backup is a leading cross-platform cloud backup and disaster recovery solution integrated with major public cloud services, such as Amazon Web Services, Microsoft Azure and Google Cloud Platform.
The Internet of Things (IoT), in all its myriad manifestations, has great potential. Much of that potential comes from the evolving data management and analytic (DMA) technologies and processes that allow us to gain insight from all of the IoT data that can be generated and gathered. This potential may never be met as those data sets are tied to specific industry verticals and single markets, with no clear way to use IoT data and sensor analytics to fulfill the hype being given the IoT today.
Ask someone to architect an Internet of Things (IoT) solution and you are guaranteed to see a reference to the cloud. This would lead you to believe that IoT requires the cloud to exist. However, there are many IoT use cases where the cloud is not feasible or desirable. In his session at @ThingsExpo, Dave McCarthy, Director of Products at Bsquare Corporation, will discuss the strategies that exist to extend intelligence directly to IoT devices and sensors, freeing them from the constraints of ...
Fifty billion connected devices and still no winning protocols standards. HTTP, WebSockets, MQTT, and CoAP seem to be leading in the IoT protocol race at the moment but many more protocols are getting introduced on a regular basis. Each protocol has its pros and cons depending on the nature of the communications. Does there really need to be only one protocol to rule them all? Of course not. In his session at @ThingsExpo, Chris Matthieu, co-founder and CTO of Octoblu, walk you through how Oct...
A completely new computing platform is on the horizon. They’re called Microservers by some, ARM Servers by others, and sometimes even ARM-based Servers. No matter what you call them, Microservers will have a huge impact on the data center and on server computing in general. Although few people are familiar with Microservers today, their impact will be felt very soon. This is a new category of computing platform that is available today and is predicted to have triple-digit growth rates for some ...
SYS-CON Events announced today that SoftNet Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. SoftNet Solutions specializes in Enterprise Solutions for Hadoop and Big Data. It offers customers the most open, robust, and value-conscious portfolio of solutions, services, and tools for the shortest route to success with Big Data. The unique differentiator is the ability to architect and ...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, will demonstrate how to move beyond today's coding paradigm ...
Everyone knows that truly innovative companies learn as they go along, pushing boundaries in response to market changes and demands. What's more of a mystery is how to balance innovation on a fresh platform built from scratch with the legacy tech stack, product suite and customers that continue to serve as the business' foundation. In his General Session at 19th Cloud Expo, Michael Chambliss, Head of Engineering at ReadyTalk, will discuss why and how ReadyTalk diverted from healthy revenue an...
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.